PO.PS01.06 · 人群科学

A multi-center hospital-based case-control study of lymphoid and myeloid neoplasms (AsiaLymph): Study design and initial findings for education, body mass index, and family history

编号 5051 展板 24 时间 4/21 09:00–12:00 区域 Section 35 主讲 Qing Lan, MD;PhD
分会场 Diet, Alcohol, and Tobacco, and Other Lifestyle Factors
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Qing Lan1, Lauren M. Hurwitz1, John K. Chan2, Tai Hing Lam3, Kexin Chen4, Yok Lam Kwong5, Xu Caigang6, Brian CH Chiu7, Raymond Liang8, Ip Dennis3, Wei Hu1, Bryan Bassig9, Mark Purdue1, Jun Xu3, Sarah Locke1, Sophia S. Wang10, James R. Cerhan11, Sonja Berndt1, Jonathan N. Hofmann1, Jianxin Shi1, Kai Yu1, Shahinaz Gadalla1, Lisa J. McReynolds1, Rena Jones1, Hongji Dai4, Zhangyan Lyu4, Lugui Qiu12, Wei Liu12, Huilai Zhang13, Xianhuo Wang13, Lindsay M. Morton1, Stephen Chanock1, Martha Linet1, Melissa C. Friesen1, Roel Vermeulen14, Nathaniel Rothman1

1NCI Div. of Cancer Epidemiology & Genetics, Bethesda, MD,2Queen Elizabeth Hospital, Hong Kong, Hong Kong,3School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong,4Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China,5Queen Mary Hospital, Hong Kong, Hong Kong,6Department of Hematology, Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, China,7Associate Professor, Dept. of Health Studies, University of Chicago, Chicago, IL,8Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong,9Saville Cancer Screening and Prevention Center, Inova Schar Cancer Institute, Inova Health System, Fairfax, VA,10City of Hope National Medical Center, Duarte, CA,11Mayo Clinic College of Medicine and Science, Rochester, MN,12Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China,13Tianjin Medical University Cancer Institute and Hospital, Tianjin, China,14Utrecht University, Utrecht, Netherlands

摘要 Abstract

Background: Epidemiologic and other studies have identified environmental, occupational, and genetic risk factors for lymphoid and myeloid malignancies, but most studies have been conducted in Western populations. Investigations in populations with differing exposure patterns, distributions of disease subtypes, and genetic architecture are needed to fully understand hematopoietic tumor etiology. Methods: We conducted a large, multicenter, hospital-based case-control study of lymphoid and myeloid neoplasms in East Asia (AsiaLymph), including 5,671 lymphoid cases, 1,879 myeloid cases, and 3,858 controls. Participants completed a computer-assisted personal interview and provided biospecimens. Cases underwent central pathology review and were coded into the WHO Classification. Herein, we describe the study methods in detail and report association results for education, body mass index, and family history. Results: Greater BMI at age 20 but not at age 40 was associated with odds of total lymphoid neoplasm (per 5 kg/m 2 increase: OR [95% CI]: 1.18 [1.09-1.27]), total myeloid neoplasm (OR [95% CI]: 1.17 [1.05-1.29]), and several subtypes. Greater educational attainment was associated with increased odds of total lymphoid neoplasm (for college vs. less than primary education: OR [95% CI]: 1.41 [1.21-1.65]) but not myeloid neoplasm (OR [95% CI]: 1.17 [0.95-1.45]; p-heterogeneity=0.02). There were also positive associations between family history of hematologic cancer in first degree relatives and odds of lymphoid neoplasm (OR [95% CI]: 1.53 [1.15-2.03]) and myeloid neoplasm (OR [95% CI]: 1.65 [1.11-2.44]) and specific subtypes. None of the evaluated risk factors were associated with NK/T-cell lymphoma, which supports a distinct etiology for this subtype. Conclusion: The AsiaLymph Study is one of the largest molecular epidemiology studies of both lymphoid and myeloid neoplasms with standardized World Health Organization classification of histopathologic subtypes and will serve as a valuable resource for etiologic investigations into risk factors for these malignancies.
利益披露 Disclosure
Q. Lan, None.. L. M. Hurwitz, None.. J. K. Chan, None.. T. Lam, None.. K. Chen, None.. Y. Kwong, None.. X. Caigang, None.. R. Liang, None.. I. Dennis, None.. W. Hu, None.. B. Bassig, None.. M. Purdue, None.. J. Xu, None.. S. Locke, None.. S. Berndt, None.. J. N. Hofmann, None.. J. Shi, None.. K. Yu, None.. S. Gadalla, None.. L. J. McReynolds, None.. R. Jones, None.. H. Dai, None.. Z. Lyu, None.. L. Qiu, None.. W. Liu, None.. H. Zhang, None.. X. Wang, None.. L. M. Morton, None.. S. Chanock, None.. M. Linet, None.. M. C. Friesen, None.. N. Rothman, None.

在会议检索中打开